USA flag logo/image

An Official Website of the United States Government

Cooled Laser Delivery System: Improved Thermal Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
59833
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
CA096227
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2005
Title: Cooled Laser Delivery System: Improved Thermal Therapy
Agency: HHS
Contract: 2R44CA096227-02A1
Award Amount: $739,092.00
 

Abstract:

DESCRIPTION (provided by applicant): The focus of this research is to continue development of a novel interstitial cooled laser delivery system for improved thermal therapy. The system is intended to find applications in the thermal destruction of cancerous tumors. Laser interstitial thermal therapy (LITT) is an ideal method for minimally invasive treatment of localized tumors, but has so far failed to gain widespread clinical acceptance due to limitations of current interstitial applicators. In Phase I, we designed, built, and tested a novel cooled laser fiber (CLF) delivery apparatus which includes an advanced integrated diffusing tip fiber optic along with an improved means for heat removal from both the fiber optic and tissue in close proximity to the applicator. We characterized the system in vitro and in vivo and demonstrated that the system was superior to non-cooled applicators for creating larger laser lesions in a safe and reliable manner. In Phase II we will extend our initial development efforts and refine the CLF device by optimizing materials, expanding size configurations, improving construction methods, and investigating optimal cooling parameters. In addition, we plan to add features to the device that will allow rotation and translation of the internal fiber optic delivery element for asymmetric lesion production. Finally we will fully characterize the complete system in primary target tissues by examining lesion sizes resulting from various laser powers, wavelengths, cooling rates, and exposure durations. A major goal throughout this work will be to acquire sufficient data necessary for completion and submission of a 510(k) application with the FDA.

Principal Investigator:

Ashok Gowda
7137410111
ashok@biotexmedical.com

Business Contact:

Roger Mcnichols
7137410111
ROGER@BIOTEXMEDICAL.COM
Small Business Information at Submission:

Biotex, Inc.
Biotex, Inc. 8058 El Rio St Houston, TX 77054

EIN/Tax ID: 742824041
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No